Introduction: The renewed clinical interest in psychedelics is often framed in ways that blur the distinction between psychotherapy and the psychedelic drug experience itself. Revisiting early research and clinical observations from the first wave of psychedelic science may help clarify how these processes were originally conceptualized. In the mid-20th century, LSD and other serotonergic...
Since the introduction of disulfiram in 1951 (the first ever Food and Drug Administration (FDA)-approved medication for substance use disorders (SUDs)) (1), only seven other individual medications have been approved for the treatment of SUDs. While the repurpose of medications and different formulations increase the total number of FDA-approved medicines (Table 1 and(2)), the arsenal of...
Music is often treated as an atmospheric accessory in psychedelic and ketamine therapy: useful, pleasant, optional, or merely calming. Across a curated evidence base of 41 studies, reviews, mechanistic papers, clinical reports, playlist-design papers, ketamine-specific studies, ceremonial-music papers, and counterarguments, music repeatedly appears as an active session-shaping variable. The...
The U.S. departments of Health and Human Services (HHS) and Veterans Affairs (VA) have entered into a five‐year agreement to coordinate research, clinical development and future implementation of rapid‐acting psychiatric treatments, including psychedelic‐based therapies, for veterans with serious mental health conditions, an HHS news release stated. Under the agreement, the agencies will expand...
Zenodo (CERN European Organization for Nuclear Research)July 17, 2026Bartosz Niciński, Magdalena Kloc, Ewa Wiench, Natasza Millan, Aleksandra Blicharz, Wojciech Kozdraś, Lidia Kozaczko, Gabriela Szewczyk, Elżbieta Bukowczan, Alicja Zając, Damian Broda, Alicja Benecka
preprint
Major depressive disorder is a highly burdensome psychiatric condition worldwide, and many patients do not achieve full remission after standard monoaminergic antidepressant treatment. This has contributed to growing interest in rapid-acting antidepressant interventionstargeting neurobiological pathways beyond traditional serotonin, norepinephrine, and dopamine mechanisms. This review...
Objective: The objective of this narrative review is to understand what forms of spirituality screening and spiritual support are available to individuals with serious or life-threating illness involved in psychedelic-assisted therapies. Introduction: In addition to physical pain related to disease and treatment processes, people encountering serious illness frequently experience psychological...
Background. The necessity of transitioning from a linear-mechanistic model of the psyche to understanding it as a dynamic predictive system is substantiated. The methodological and applied prospects of such a transformation for psychology and psychotherapy are demonstrated. Modern concepts in the philosophy of mind, psychology, and neuroscience that treat the psyche as a self-organizing system...
Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging...
Background: When administered alongside monitoring and support, psilocybin has shown promise in the treatment of multiple psychiatric conditions. However, the contribution and nature of participant support in the context of psychedelic trials are much debated. Aims: We sought to further illustrate the structure and format of the monitoring and support used in Compass Pathfinder Ltd (Compass)...
Psychedelics such as psilocybin have been linked to enhanced neuroplasticity and symptom relief in affective disorders, but the neurobiological mechanisms and impact of environmental context remain unclear. Here, we tested whether a single dose of psilocybin (0.3 mg/kg) alters synaptic density in healthy individuals and whether setting-dependent subjective experience shapes this effect. Fifteen...